anti-ICAD (Inhibitor of CAD DFF45), pAb

CHF 315.00
In stock
YIF-LF-PA0058100 µlCHF 315.00
More Information
Product Details
Synonyms H13; DFFA; ICAD; DFF1; DFF-45; Inhibitor of CAD; DNA Fragmentation Factor Subunit α; DNA Fragmentation Factor 45 kDa Subunit
Product Type Polyclonal Antibody
Immunogen/Antigen Synthetic peptide.

Western Blot (1:2,000)
Immunoprecipitation not tested.

Crossreactivity Human
Purity Detail Protein A purified.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

The inhibitor of caspase-3-activated DNase (ICAD) is a caspase-3 substrate that controls nuclear apoptosis. ICAD has two isoforms: a functional isoform of M.W. 45kDa, ICAD-L/DNA fragmentation factor (DFF) 45; and a M.W. 35kDa isoform, ICAD-S/DFF35. Although both ICAD-L and ICAD-S can bind and inhibit CAD, only ICAD-L was reported to be functional. ICAD is cleaved to be inactivated and allow caspase-activated DNase (CAD) to execute nuclear internucleosomal apoptotic DNA fragmentation. In non-apoptotic cells, CAD is complexed with its inhibitor, ICAD. The activation of the CAD/ICAD complex occurs through the caspase 3-mediated cleavage of ICAD at residues 117 and 224, which results in three ICAD fragments that are then released from CAD. In addition to its DNase inhibitory activity, ICAD acts as a CAD-specific folding chaperone. There are recent reports that ICAD is a potential target for restoring a normal apoptotic signal transduction pathway in colon and brain cancer cells. Inhibitor of the caspase-activated DNase (DFF40).

Product References

1) Enari M et al, Nature. 1998; vol.391(6662): pp.43-50. (General)
2) Sakahira H et al, J Biol Chem. 1999; vol.274(22): p.15740-4. (General)
3) Charrier L et al, Cancer Res. 2002; vol.62(7): p.2169-74. (General)
4) Fukushima K et al, J Mol Biol. 2002; vol.321(2): p.317-27. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.